Abstract:Objective The benefits of IL-35 treatment have been verified in multiple animal models of diseases, while its influence on T cells immunity under normal condition still needs to be elucidated. The present study was designed to investigate the effects modulating IL-35 levels in vivo and in vitro on T cells, response and also the effects on T cells subsets in normal mice. Methods A plasmid pMSCV-IL-35-GFP carrying mouse linear IL-35 fragment with two subunits joint together was constructed and the heterodimer expression was confirmed. Normal mice were randomly divided into three groups and received an intravenous injection of PBS, pMSCV-GFP and pMSCV-IL-35-GFP respectively. After 72 h, spleen tissues and peripheral blood were harvested for following analysis. Meanwhile, splenic T cells were isolated and incubated with 10, 30, or 50 ng/mL recombinant IL-35 factor for 24 h with the addition of anti-CD3/CD28 in vitro. T-cell subsets were assessed by Fluorescence activated cell sorting (FACS) and related cytokines together with effector molecules were determined by real time PCR. Results Western blotting confirmed a 52 kDa band in the cell lysate of HEK 293T transducted with pMSCV-IL-35-GFP plasmid, indicating a successful expression of IL-35. Ebi3 and IL-12A, two subunits of IL-35, could be identified 72 h post DNA injection. IL-35 upregulation in vivo effectively inhibit CD4+ and CD8+ T cell proliferation and Th1 cytokine secretion. Effector molecules of CD8+ T cells were also remarkably suppressed. On the contrary, high level of IL-35 significantly induced CD4+ CD25+ Tregs and Th2 enhancement. The in vitro study provided similar results. Conclusion The results indicated Th1 and CD8+ T cell inhibition and Th2 and Tregs bias in the presence of IL-35 under a normal state which partly contributed to its therapeutic potential.

Recent Advances in the Study of the Novel Inhibitory Cytokine IL-35

JAK/STAT Signaling is Involved in IL-35-induced Inhibition of Hepatitis B Virus Antigen-Specific Cytotoxic T Cell Exhaustion in Chronic Hepatitis B

Immunomodulation of Interleukin-34 and Its Potential Significance As a Disease Biomarker and Therapeutic Target

Biological functions and clinical implications of interleukin-34 in inflammatory diseases

The Immunobiology of Interleukin-35 and Its Regulation and Gene Expression.

Immunomodulatory effects of iTr35 cell subpopulation and its research progress

Research progresses of IL-35 in autoimmune diseases

Proteomics analysis reveals the interleukin-35-dependent regulatory mechanisms affecting CD8<SUP>+</SUP> T-cell functions

IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment

Interleukin-35: the future of hyperimmune-related diseases?

Interleukin 35 Induced Th2 and Tregs Bias under Normal Conditions in Mice

IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases.

Novel insights into IL-37: an anti-inflammatory cytokine with emerging roles in anti-cancer process

IL-35 Inhibits HBV Antigen-Specific IFN-γ-producing CTLs in Vitro.

Cmar_a_262745 7527..7537

Interleukin-35 in autoimmune dermatoses: Current concepts

Elevated level of Interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1/STAT3

Immune Function of Interleukin-33 and Its Relation to Human Diseases

The Role of IL-35 in the Pathophysiological Processes of Liver Disease

The Molecular Role of IL-35 in Non-Small Cell Lung Cancer

Interleukin-35: A key player managing pre-diabetes and chronic inflammatory type 1 autoimmune diabetes